申请人:Millennium Pharmaceuticals, Inc.
公开号:US06348487B1
公开(公告)日:2002-02-19
Benzimidazole derivatives of Formula I or a pharmaceutically acceptable salt thereof are MCP-1 antagonists and are thus useful in the treatment of inflammation, atherosclerosis, restenosis, and immune disorders
wherein A is N or CH;
where W, X, Y, and Z can be independently C—R2, C—R3, C—R4, C—R5, or N;
no more than two of W, X, Y, and Z can be N in any one structure,
R2, R3, R4, and R5 are as define in the specification.
公式I中的苯并咪唑衍生物或其药学上可接受的盐是MCP-1拮抗剂,因此可用于治疗炎症,动脉粥样硬化,再狭窄和免疫性疾病,其中A为N或CH;其中W,X,Y和Z可以独立地为C—R2,C—R3,C—R4,C—R5或N;在任何一个结构中,W,X,Y和Z中最多只能有两个为N;R2,R3,R4和R5的定义如规范中所述。